Fig. 6From: The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus(Reprinted with permission from Neal [16])The CANVAS Program: composite of 40% reduction in eGFR, ESKD, or renal death. eGFR, estimated glomerular filtration rate; CI, confidence intervalBack to article page